Applied Filters
A helping hand for rare diseases
Companies researching and commercialising drugs for rare diseases face unusual challenges in protecting their inventions, as Michael Yamauchi, director and patent counsel at Alexion Pharmaceuticals, tells LSIPR in an interview.
LSIPR 50 2017: Leda Trivinos—Playing the long game
Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.
LSIPR 50 2017: James Topper—Venturing into biotech
Frazier Healthcare Partners has been responsible for creating and investing in multiple biotech companies, developing products from novel antibiotics to cancer therapies. James Topper, Frazier’s managing general partner, explains the firm’s philosophy.
LSIPR 50 2017: Arabella Cecil—No more hand to mouth
BACIT, a former fund of funds, has combined with life sciences investment company Syncona to form a new investment vehicle using the latter’s name. LSIPR speaks to Arabella Cecil, one of the co-founders of BACIT, about the new company’s vision.
LSIPR 50 2017: Larry Coury—The art of successful litigation
Resolving complex legal disputes and explaining technical concepts in a courtroom are all part of the job for Regeneron’s Larry Coury, who talks to LSIPR about life as senior director of dispute resolution.
LSIPR 50: Daniela Verthelyi—Safety first
Finding therapies that are safe, effective and available requires hard work and putting patients first, according to Daniela Verthelyi of the FDA, who discusses her role as chief of the immunology laboratory at the government agency.
LSIPR 50 2017: Sean Dennehey—Steering the ship
From the Unified Patent Court to life sciences industrial strategy, there are many issues for Sean Dennehey to contend with as deputy CEO of the UK Intellectual Property Office. He talks to LSIPR about how he managed.
LSIPR 50 2017: Steve Bates—Dreaming big for UK bioscience
As CEO of the UK BioIndustry Association, Steve Bates works closely with industry and government and, by 2025, he wants the UK to become home to the third biggest global biotech cluster, as he explains to LSIPR.
LSIPR 50 2017: Jennifer Doudna
Jennifer Doudna was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2017: Feng Zhang
Feng Zhang was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
